A circulating tumor cell is shed into the vasculature from the primary tumor and is carried around the body with the help of blood circulation. These circulating tumor cells are an indication of metastatic disease, and their detection can help in diagnosing the disease in its early stages and designing an appropriate treatment regime for the patient. In recent years, there have been significant advancements in isolation methods of circulating tumor cells for diagnosis. Immunoaffinity, physical properties, and direct analysis are among a few of the approaches used for circulating tumor cell isolation. Immunoaffinity is the affinity reactions that capture antibodies and target antigens present on cells of interest using magnetic beads, microfluidic flow, nanostructured substrate, microtubes, and leucocyte depletion. The microtube approach uses the biomimetic approach to stimulate the procedure of selectin-mediated cell adhesion for capturing CTCs. Even at a high flow rate of 4.8 ml/h, selectin-coated microtubes induce cell attachment and rolling, which promotes CTC binding with anti-EpCAM (i.e., epithelial cell adhesion molecule) and anti-PSMA antibodies. The device had a capture efficiency of 50% and an average purity of 66%, and it detected circulating tumor cells in 14 of 14 patient blood samples examined, compared to 9 of 14 detected by the CellSearch system. Physical properties are also used to isolate circulating tumor cells from peripheral blood cells. A few of the common physical properties used for the isolation of CTCs are density gradient centrifugation, microfiltration, microfluidics, and dielectrophoresis. Thus, the ongoing developments and advancements in various isolation techniques for circulating tumor cells are expected to gain traction in the coming years.
During the COVID19 pandemic, healthcare providers had to reduce the number of diagnostic services and screening programs to redirect their efforts on the management of this disease. As a result, cancer patients became more susceptible to serious infections and faced issues such as interrupted cancer or standard medical care. Increased pressure from elevated hospitalization rates for COVID-19 patients led to the reprofiling of many hospitals and departments, including oncology clinics, to treat COVID-19 patients. These factors harmed the progress of the Middle East and Africa circulating tumor cell (CTC) diagnostics market.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the circulating tumor cell (CTC) diagnostics market. The Middle East & Africa circulating tumor cell (CTC) diagnostics market is expected to grow at a good CAGR during the forecast period.

Middle East & Africa Circulating Tumor Cell (CTC) Diagnostics Market Segmentation
By Technology
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 75.3 Million |
| Market Size by 2028 | US$ 131.3 Million |
| CAGR (2021 - 2028) | 8.3% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Technology
|
|
Regions and Countries Covered
|
|
| Middle East and Africa | South Africa, Saudi Arabia, UAE, Rest of Middle East and Africa |
| Market leaders and key company profiles |
|
The Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics Market is valued at US$ 75.3 Million in 2021, it is projected to reach US$ 131.3 Million by 2028.
As per our report Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics Market, the market size is valued at US$ 75.3 Million in 2021, projecting it to reach US$ 131.3 Million by 2028. This translates to a CAGR of approximately 8.3% during the forecast period.
The Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics Market report:
The Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)